Payment overview · 2025
General Payments
$12,132.36
182 reported records · 20 companies
Healthcare provider profile · identity verified
Jeffrey J Senfield, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Clinical Cardiac Electrophysiology · GREENVILLE, SC · NPI 1871727073
Verified facts
What the public records show
CMS Open Payments records show Jeffrey J Senfield, MD received $12,132.36 in general payments during 2025 across 182 reported records.
Impulse Dynamics (USA) Inc. accounted for 34.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 39 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 677 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Impulse Dynamics (USA) Inc. | Unresolved — no canonical attribution shown | $4,147.51 | 34.2% | 17 | 2025 |
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $4,058.03 | 33.5% | 17 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $1,039.59 | 8.6% | 35 | 2025 |
| AtriCure, Inc. | Unresolved — no canonical attribution shown | $620.94 | 5.1% | 11 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $448.66 | 3.7% | 22 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$416.43 | 3.4% | 17 | 2025 |
| Biosense Webster, Inc. | Unresolved — no canonical attribution shown | $301.39 | 2.5% | 25 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $221.85 | 1.8% | 4 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $157.14 | 1.3% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $141.94 | 1.2% | 10 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $124.34 | 1.0% | 6 | 2025 |
| Elutia, Inc. | Unresolved — no canonical attribution shown | $111.94 | 0.9% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $69.50 | 0.6% | 3 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $66.65 | 0.6% | 2 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $56.15 | 0.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $46.74 | 0.4% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $35.15 | 0.3% | 2 | 2025 |
| Davol Inc. | Unresolved — no canonical attribution shown | $25.94 | 0.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.49 | 0.2% | 1 | 2025 |
| Becton, Dickinson and Company | Unresolved — no canonical attribution shown | $20.98 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $5,054.57 | 173 |
| Consulting Fee | $3,100.00 | 3 |
| Honoraria | $2,800.00 | 2 |
| Travel and Lodging | $1,177.79 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Optimizer Normalized: optimizer |
Device | Impulse Dynamics (USA) Inc. | $4,147.51 | 17 | 2025 |
Source payment records
|
|||||
| EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX Normalized: epi sense guided coagulation system with visitrax |
Device | AtriCure, Inc. | $601.38 | 10 | 2025 |
Source payment records
|
|||||
| FARAPULSE Normalized: farapulse |
Device | Boston Scientific Corporation | $524.49 | 19 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $448.66 | 22 | 2025 |
Source payment records
|
|||||
| CARTO 3 Normalized: carto 3 |
Device | Biosense Webster, Inc. | $301.39 | 25 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $281.55 | 9 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $221.85 | 4 | 2025 |
Source payment records
|
|||||
| Acticor 7 VR-T DX Normalized: acticor 7 vr t dx |
Device | BIOTRONIK INC. | $151.32 | 2 | 2025 |
Source payment records
|
|||||
| MICRA Normalized: micra |
Device | Medtronic, Inc. | $147.29 | 4 | 2025 |
Source payment records
|
|||||
| AURORA EV-ICD MRI SURESCAN Normalized: aurora ev icd mri surescan |
Device | Medtronic, Inc. | $140.73 | 1 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $136.04 | 3 | 2025 |
Source payment records
|
|||||
| ECM Patch,Pouch Normalized: ecm patch pouch |
Device | Elutia, Inc. | $111.94 | 1 | 2025 |
Source payment records
|
|||||
| ECC Solutions Normalized: ecc solutions |
Device | Philips North America LLC | $109.35 | 2 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP VVCS 6-12F Normalized: cardiva vascade mvp vvcs 6 12f |
Device | CARDIVA MEDICAL, INC. | $104.04 | 5 | 2025 |
Source payment records
|
|||||
| LINQ II Normalized: linq ii |
Device | Medtronic, Inc. | $82.92 | 8 | 2025 |
Source payment records
|
|||||
| EMBLEM MRI S-ICD Normalized: emblem mri s icd |
Device | Boston Scientific Corporation | $75.77 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $69.50 | 3 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $66.65 | 2 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $56.15 | 1 | 2025 |
Source payment records
|
|||||
| Ambulatory Monitoring & Diagnostics Undivided Normalized: ambulatory monitoring diagnostics undivided |
Device | Philips North America LLC | $47.79 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $46.74 | 2 | 2025 |
Source payment records
|
|||||
| GALLANT Normalized: gallant |
Device | Abbott Laboratories | $39.48 | 3 | 2025 |
Source payment records
|
|||||
| XIENCE SKYPOINT Normalized: xience skypoint |
Device | Abbott Laboratories | $28.31 | 1 | 2025 |
Source payment records
|
|||||
| ENSITE Normalized: ensite |
Device | Abbott Laboratories | $24.99 | 1 | 2025 |
Source payment records
|
|||||
| AGILIS Normalized: agilis |
Device | Abbott Laboratories | $22.05 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.49 | 1 | 2025 |
Source payment records
|
|||||
| HemoSphere Normalized: hemosphere |
Device | Becton, Dickinson and Company | $20.98 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP XL VVCS 10-12F Normalized: cardiva vascade mvp xl vvcs 10 12f |
Device | CARDIVA MEDICAL, INC. | $20.30 | 1 | 2025 |
Source payment records
|
|||||
| AMVIA EDGE Normalized: amvia edge |
Device | BIOTRONIK INC. | $20.18 | 1 | 2025 |
Source payment records
|
|||||
| ATRICLIP LAA EXCLUSION SYSTEM Normalized: atriclip laa exclusion system |
Device | AtriCure, Inc. | $19.56 | 1 | 2025 |
Source payment records
|
|||||
| SYNERGY ABLATION SYSTEM Normalized: synergy ablation system |
Device | AtriCure, Inc. | $19.56 | 1 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $17.23 | 1 | 2025 |
Source payment records
|
|||||
| COBALT DR MRI SURESCAN Normalized: cobalt dr mri surescan |
Device | Medtronic, Inc. | $15.60 | 1 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $15.03 | 2 | 2025 |
Source payment records
|
|||||
| SQ-RX PULSE GENERATOR Normalized: sq rx pulse generator |
Device | Boston Scientific Corporation | $14.84 | 1 | 2025 |
Source payment records
|
|||||
| AZURE XT DR MRI SURESCAN Normalized: azure xt dr mri surescan |
Device | Medtronic, Inc. | $12.66 | 2 | 2025 |
Source payment records
|
|||||
| General - Brady Normalized: general brady |
Device | Boston Scientific Corporation | $6.90 | 1 | 2025 |
Source payment records
|
|||||
| ASSURITY Normalized: assurity |
Device | Abbott Laboratories | $6.86 | 1 | 2025 |
Source payment records
|
|||||
| HI-TORQUE COMMAND Normalized: hi torque command |
Device | Abbott Laboratories | $5.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 677 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
677 | 166 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 677 | 166 |
| Metoprolol Succinate | Metoprolol Succinate | 447 | 132 |
| Flecainide Acetate | Flecainide Acetate | 222 | 75 |
| Xarelto | Rivaroxaban | 208 | 48 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 176 | 66 |
| Metoprolol Tartrate | Metoprolol Tartrate | 126 | 44 |
| Losartan Potassium | Losartan Potassium | 104 | 38 |
| Dofetilide | Dofetilide | 98 | 25 |
| Amiodarone Hcl | Amiodarone Hcl | 93 | 33 |
| Amlodipine Besylate | Amlodipine Besylate | 93 | 36 |
| Carvedilol | Carvedilol | 93 | 38 |
| Furosemide | Furosemide | 82 | 38 |
| Sotalol | Sotalol Hcl | 79 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 59 | 47 |
| Atorvastatin Calcium | Atorvastatin Calcium | 57 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 56 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 52 | 43 |
| Sucralfate | Sucralfate | 47 | 46 |
| Colchicine | Colchicine | 46 | 45 |
| Lisinopril | Lisinopril | 37 | 16 |
| Jardiance | Empagliflozin | 26 | suppressed |
| Multaq | Dronedarone Hcl | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 17 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 16 | suppressed |
| Potassium Chloride | Potassium Chloride | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $12,132.36 · 182 records | Impulse Dynamics (USA) Inc. | AGILIS, AMVIA EDGE, ASSURITY, ATRICLIP LAA EXCLUSION SYSTEM, AURORA EV-ICD MRI SURESCAN, AZURE XT DR MRI SURESCAN, Acticor 7 VR-T DX, Ambulatory Monitoring & Diagnostics Undivided, Barostim Neo System, CARDIVA VASCADE MVP VVCS 6-12F, CARDIVA VASCADE MVP XL VVCS 10-12F, CARTO 3, COBALT DR MRI SURESCAN, COREVALVE EVOLUT R, ECC Solutions, ECM Patch,Pouch, ELIQUIS, EMBLEM MRI S-ICD, ENSITE, EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX, ESPRIT, FARAPULSE, FFRct, GALLANT, General - Brady, General - Therapies, HI-TORQUE COMMAND, HemoSphere, LEQVIO, LINQ II, LifeVest, MICRA, ONPATTRO, Optimizer, SQ-RX PULSE GENERATOR, SYNERGY ABLATION SYSTEM, WATCHMAN FLX, Wegovy, XIENCE SKYPOINT | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novartis Pharmaceuticals Corporation?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error